Jeremy Wohlwend

Jeremy Wohlwend

Auto-generated profile, based on publicly available information

Jeremy Wohlwend

Center Broad Institute of MIT and Harvard CSAIL Massachusetts Institute of Technology

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 June 2025 in bioRxiv
Verified
Preprint
Open access
SPSaro Passaro
Saro Passaro
GCGabriele Corso
Gabriele Corso
JWJeremy Wohlwend
Jeremy Wohlwend
MRMateo Reveiz
Mateo Reveiz
STStephan Thaler
Stephan Thaler
RBRegina Barzilay
Regina Barzilay
Accurately modeling biomolecular interactions is a central challenge in modern biology. While recent advances, such as AlphaFold3 and Boltz-1, have substantially improved our ability to predict biomolecular complex structures, these models still fall short in predicting binding affinity, a critical property underlying molecular function and therapeutic efficacy. Here, we present Boltz-2, a new structural biology foundation model that exhibits strong performance for both structure and affinity prediction. Boltz-2 introduces controllability features including experimental method conditioning, distance constraints, and multi-chain template integration for structure prediction, and is, to our knowledge, the first AI model to approach the performance of free-energy perturbation (FEP) methods in estimating small molecule–protein binding affinity. Crucially, it achieves strong correlation with experimental readouts on many benchmarks, while being at least 1000 × more computationally efficient than FEP. By coupling Boltz-2 with a generative model for small molecules, we demonstrate an effective workflow to find diverse, synthesizable, high-affinity binders, as estimated by absolute FEP simulations on the TYK2 target. To foster broad adoption and further innovation at the intersection of machine learning and biology, we are releasing Boltz-2 weights, inference, and training code 1 under a permissive open license, providing a robust and extensible foundation for both academic and industrial research.

20 November 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
JWJeremy Wohlwend
Jeremy Wohlwend
GCGabriele Corso
Gabriele Corso
SPSaro Passaro
Saro Passaro
NGNoah Getz
Noah Getz
MRMateo Reveiz
Mateo Reveiz
RBRegina Barzilay
Regina Barzilay
Understanding biomolecular interactions is fundamental to advancing fields like drug discovery and protein design. In this paper, we introduce B oltz -1, an open-source deep learning model incorporating innovations in model architecture, speed optimization, and data processing achieving A lpha F old 3-level accuracy in predicting the 3D structures of biomolecular complexes. B oltz -1 demonstrates a performance on-par with state-of-the-art commercial models on a range of diverse benchmarks, setting a new benchmark for commercially accessible tools in structural biology. Further, we push the boundary of capabilities of these models with B oltz-steering , a new inference time steering technique that is able to fix hallucinations and non-physical predictions from the models. By releasing the training and inference code, model weights, datasets, and benchmarks under the MIT open license, we aim to foster global collaboration, accelerate discoveries, and provide a robust platform for advancing biomolecular modeling.

28 January 2025 in Nature Machine Intelligence
Verified
Journal Article
Open access
PDF file
JWJeremy Wohlwend
Jeremy Wohlwend
ANAnusha Nathan
Anusha Nathan
NSNitan Shalon
Nitan Shalon
CCCharles R. Crain
Charles R. Crain
RTRhoda Tano-Menka
Rhoda Tano-Menka
RBRegina Barzilay
Regina Barzilay
Accurate in silico determination of CD8+ T cell epitopes would greatly enhance T cell-based vaccine development, but current prediction models are not reliably successful. Here, motivated by recent successes applying machine learning to complex biology, we curated a dataset of 651,237 unique human leukocyte antigen class I (HLA-I) ligands and developed MUNIS, a deep learning model that identifies peptides presented by HLA-I alleles. MUNIS shows improved performance compared with existing models in predicting peptide presentation and CD8+ T cell epitope immunodominance hierarchies. Moreover, application of MUNIS to proteins from Epstein–Barr virus led to successful identification of both established and novel HLA-I epitopes which were experimentally validated by in vitro HLA-I-peptide stability and T cell immunogenicity assays. MUNIS performs comparably to an experimental stability assay in terms of immunogenicity prediction, suggesting that deep learning can reduce experimental burden and accelerate identification of CD8+ T cell epitopes for rapid T cell vaccine development.

27 January 2022 in arXiv
Verified
Preprint
Open access
PDF file
WJWengong Jin
Wengong Jin
JWJeremy Wohlwend
Jeremy Wohlwend
RBRegina Barzilay
Regina Barzilay
TJTommi Jaakkola
Tommi Jaakkola
Antibodies are versatile proteins that bind to pathogens like viruses and stimulate the adaptive immune system. The specificity of antibody binding is determined by complementarity-determining regions (CDRs) at the tips of these Y-shaped proteins. In this paper, we propose a generative model to automatically design the CDRs of antibodies with enhanced binding specificity or neutralization capabilities. Previous generative approaches formulate protein design as a structure-conditioned sequence generation task, assuming the desired 3D structure is given a priori. In contrast, we propose to co-design the sequence and 3D structure of CDRs as graphs. Our model unravels a sequence autoregressively while iteratively refining its predicted global structure. The inferred structure in turn guides subsequent residue choices. For efficiency, we model the conditional dependence between residues inside and outside of a CDR in a coarse-grained manner. Our method achieves superior log-likelihood on the test set and outperforms previous baselines in designing antibodies capable of neutralizing the SARS-CoV-2 virus.

6 July 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
NGNoah Getz
Noah Getz
GSGeoffrey Smith
Geoffrey Smith
ACAvene Colgan
Avene Colgan
VFVincent Fan
Vincent Fan
LCLuca Cavalleri
Luca Cavalleri
SPSaro Passaro
Saro Passaro
We present BoltzMol-1, a small-molecule hit discovery pipeline, centered on an optimized version of Boltz-2, explicitly adapted for prospective discovery. Reliable hit discovery that generalizes across target classes (rather than only the well-characterized families that dominate existing ligand data) would broaden the range of biology accessible to small-molecule intervention and reduce reliance on resource-intensive high-throughput screening. Towards this goal, the system prioritizes compounds for rapid experimental validation by coupling model-driven ranking with streamlined procurement from commercial catalogs. To improve developability at the point of selection, we introduce a suite of ADMET models for kinetic solubility (logS), lipophilicity (logD), and Caco-2 permeability. These models act as an early triage layer, systematically filtering out compounds with unfavorable physicochemical and absorption properties prior to synthesis or purchase. Across a panel of ten targets (most with no representation in the underlying affinity training data) we observe strong prospective performance on challenging systems. Functional actives or binders were identified for 6 of 10 targets, despite modest experimental budgets of 28-96 compounds per target. These results include successes on receptors and enzymes traditionally considered difficult for structure- or ligand-based approaches. Collectively, this work establishes a practical framework for low-throughput, cost-constrained discovery campaigns capable of delivering chemically tractable binders with favorable property profiles. Figure 1: Overview of the prospective virtual-screening campaigns across all targets. For each target, the panel shows the predicted protein-ligand complex together with the number of compounds tested, the number of confirmed actives/binders, and the assays used for screening and follow-up.

3 October 2024 in Research Square
Verified
Preprint
Open access
PDF file
WSWenxian Shi
Wenxian Shi
JWJeremy Wohlwend
Jeremy Wohlwend
MWMenghua Wu
Menghua Wu
RBRegina Barzilay
Regina Barzilay
Current vaccines provide limited protection against rapidly evolving viruses. For example, the influenza vaccine's effectiveness has averaged below 40% for the past ten years. Today, clinical outcomes of vaccine effectiveness can only be assessed retrospectively. Prospective estimation of their effectiveness is crucial but remains under-explored. In this paper, we propose an in-silico method named VaxSeer that predicts expected vaccine effectiveness by considering both the future dominance of circulating viruses and antigenic profiles of vaccine candidates. Based on ten years of historical WHO data, our approach consistently selects superior strains than the annual recommendations. Finally, the prospective score we propose exhibits a strong correlation with retrospective vaccine effectiveness and reduced disease burden, highlighting the promise of this framework in driving the vaccine selection process. Predictions from our model for the 2024 and future winter seasons are available at https://wxsh1213.github.io/vaxseer.github.io/.